Antibody · 폐암 (NSCLC)

5개 · ADC 890 · Antibody 4097 · CGT 2985 · 다음 갱신 D-6 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved5 programs
AntibodyLimited DatastaleDwight OwenPhase 1

Adenosine A2B Receptor Antagonist PBF-1129 (Adenosine A2B Receptor Antagonist PBF-1129)

Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma · Metastatic Lung Non-Small Cell Carcinoma

#MetastaticLungNon-SmallCellCarci#Antibody#Phase1#monoclonal-antibody#RecurrentLungNon-SmallCellCarcin+1
Trials 2Status Recruiting
AntibodyLimited DatastaleRoswell Park Cancer InstitutePhase 1

Nimotuzumab (Nimotuzumab)

EGFR Gene Mutation; Recurrent Non-Small Cell Lung Carcinoma · Advanced Cancer

#AdvancedCancer#Antibody#Phase1#monoclonal-antibody#EGFRGeneMutation+2
Trials 2Status Active
AntibodyLimited DatastaleWashington University School of…Phase 2

Nogapendekin alfa inbakicept (Nogapendekin alfa inbakicept)

Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent · Non-small Cell Lung Cancer Stage IV

#Non-smallCellLungCancerStageIV#Antibody#Phase2#monoclonal-antibody#Non-smallCellLungCancerRecurrent+1
Trials 1Status Recruiting
AntibodyLimited DatastaleSWOG Cancer Research NetworkPreclinical

Rilotumumab (Rilotumumab)

Recurrent Squamous Cell Lung Carcinoma; Stage IV Squamous Cell Lung Carcinoma AJCC v7 · Recurrent Squamous Cell Lung Carcinoma

#RecurrentSquamousCellLungCarcino#Antibody#Preclinical#monoclonal-antibody#StageIVSquamousCellLungCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleNational Cancer Institute (NCI)Phase 2

cixutumumab (cixutumumab)

Recurrent Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer

#RecurrentNon-smallCellLungCancer#Antibody#Phase2#monoclonal-antibody#StageIIIBNon-smallCellLungCancer+1
Trials 1Status Active